[{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MGD013","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MGD013","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MGC018","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.90000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.90000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MGD019","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MGA012","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Carboplatin","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Carboplatin","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bispecific Antibody-based Therapy","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"MacroGenics","amount2":1.46,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.46,"dosageForm":"","sponsorNew":"MacroGenics \/ Zai Lab","highestDevelopmentStatusID":"4","companyTruncated":"MacroGenics \/ Zai Lab"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Enoblituzumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"MacroGenics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Provention Bio","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenics \/ Provention Bio"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"MGD024","moa":"CD123\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":1.76,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.76,"dosageForm":"","sponsorNew":"MacroGenics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Gilead Sciences"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"MacroGenics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lorigerlimab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"MacroGenics","amount2":2.2000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"2","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Retifanlimab-dlwr","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"MacroGenics","amount2":0.90000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.90000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Vobramitamab Duocarmazine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MacroGenics","amount2":0.91000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"TerSera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Margetuximab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MacroGenics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MacroGenics \/ TerSera Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenics \/ TerSera Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by MacroGenics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
